Idioma:

Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients

Adati, Elen Monteiro ; Silva, Paula Moreira ; Sumita, Laura Massami ; Rodrigues, Marina de Oliveira ; Zanetti, Lilian P. ; Santos, Ana Cláudia F. ; Souza, Mair P. ; Colturato, Vergilio R. ; Machado, Clarisse M.

Transplant infectious disease, 2020-06, Vol.22 (3), p.e13258-n/a [Periódico revisado por pares]

Denmark: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients
Autor: Adati, Elen Monteiro ; Silva, Paula Moreira ; Sumita, Laura Massami ; Rodrigues, Marina de Oliveira ; Zanetti, Lilian P. ; Santos, Ana Cláudia F. ; Souza, Mair P. ; Colturato, Vergilio R. ; Machado, Clarisse M.
Assuntos: Adolescent ; Adult ; Aged ; Antibodies ; Antibodies, Viral - blood ; Cell number ; Clinical trials ; Developing Countries ; Dosage ; Female ; hematopoietic stem cell transplantation ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic stem cells ; Hepatitis ; Hepatitis A ; Hepatitis A - prevention & control ; Hepatitis A Vaccines - administration & dosage ; Hepatitis A Vaccines - immunology ; Hepatitis A virus ; Humans ; immunity ; Immunization ; Immunogenicity, Vaccine ; LDCs ; Lymphocytes ; Male ; Middle Aged ; Prospective Studies ; Schedules ; Seroepidemiologic Studies ; Serology ; Stem cell transplantation ; Stem cells ; Vaccination ; Vaccines ; Viruses ; Young Adult
É parte de: Transplant infectious disease, 2020-06, Vol.22 (3), p.e13258-n/a
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Background Hepatitis A virus (HAV) infection is highly prevalent in developing countries. In countries experiencing a shift from intermediate/high endemicity to low endemicity, the World Health Organization recommends the incorporation of HAV vaccine into the national vaccination calendar for children aged ≥1 year. Since HAV antibodies wane over time, most HSCT revaccination guidelines advise vaccination as optional, following the country recommendation. However, no study has evaluated the serological response to HAV vaccine in allogeneic HSCT recipients. Methods We conducted a prospective study in 46 HSCT recipients who received two doses of inactivated HAV vaccine. Blood samples were taken before vaccination to determine HAV prevalence rates, and before and 4‐6 weeks after the second dose. Specific anti‐HAV antibodies were detected by a competitive commercial enzyme immune assay. Results Patients received the first dose of vaccine at a median of 332.5 (120‐4134) days after HSCT. Median absolute lymphocyte count at vaccination was 1947 (696‐12 500)/mm3. The seroprevalence rate was 93.5% at inclusion. Although safe and well tolerated, the serological response to HAV vaccine in susceptible patients was poor (33%), and no boost effect was observed in seropositive patients. Conclusions In areas with intermediate/high seroprevalence of HAV, serology should be recommended prior to referral to vaccination. The mechanisms of antibody interference and how to overcome T‐cell function deficiency need to be better understood in transplant populations receiving HAV vaccine. Alternative schedules of HAV vaccination should be evaluated in prospective trials.
Editor: Denmark: Wiley Subscription Services, Inc
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 2 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Poor response to hepatitis A vaccination in hematopoietic stem cell transplant recipients

Adati, Elen Monteiro ; Silva, Paula Moreira ; Sumita, Laura Massami ; Rodrigues, Marina de Oliveira ; Zanetti, Lilian P. ; Santos, Ana Cláudia F. ; Souza, Mair P. ; Colturato, Vergilio R. ; Machado, Clarisse M.

Denmark: Wiley Subscription Services, Inc

Buscando em bases de dados remotas. Favor aguardar.